Patent protection of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma in Europe OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage ...

The European Patent Office has provided notice of intention to grant the Company’s composition of matter patent for GTX-104, an IV formulation of nimodipine for use in the treatment of patients ...

Thus, it is now clear that any issued patent, regardless of its current status or validity, can be Section 102 (e) (2) (pre-AIA) prior art if the other statutory requirements are met.

The patent demonstrates that NM-102, which can prevent disruption of and/or restore the functional integrity of the ileal and/or colonic intestinal barrier, can improve the benefit of immune ...

U.S.C. §102 (e) serves as a barrier to patentability if the subject invention was described in “a patent granted on an application for patent by another filed in the United States before the ...

Wells Fargo & Co. was told to pay $102.8 million after a federal jury in Texas said in infringed United Services Automobile Association’s patents for a mobile deposit system.

Two sections of the Patent Act are acknowledged as the significant gates to patentability in the United States. Among those, § 102 is a barrier against an invention that lacks novelty, and § 103 ...

ONCOS-102 is currently being tested in mesothelioma, melanoma ovarian and colorectal cancers and has already shown promising clinical results both as monotherapy and in combination with ...

* Composition of matter patent protects Targovax's lead product from its oncos platform, oncolytic viral product oncos-102 and expires in 2029 Source text for Eikon ...

The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma.